Mar. 18 at 12:59 PM
$FBIO $DERM Good to see only 1 week until DERM results. If Emrosi scripts have grown even modestly, this could tip the company into profitability. This would be big news for both companies for a few reasons 1. It would demonstrate to potential partners that licensing Emrosi could be a profitable venture, opening up further avenues for growth. 2. As much as I like DERM, their valuation is mostly underpinned by sales with a less-than-perfect cash balance. Getting some organic income would really help with shoring up the balance sheet and hopefully attract more institutional investment. 3. For Fortress, this would further validate the business model and help smooth out those 10-k numbers ahead of the PRV proceeds hitting the books in Q1 reporting.
